Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by